Health & Medicine · Cardiology
23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025)
About & call for papers
The 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) is dedicated to insulin resistance, obesity, diabetes, related Kidney, cardiovascular disease and fatty liver morbidity. Topics - The effect of lipotoxicity and th… Read more
The 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC 2025) is dedicated to insulin resistance, obesity, diabetes, related Kidney, cardiovascular disease and fatty liver morbidity. Topics - The effect of lipotoxicity and the pathophysiology of CVD - The relationship between diabetes, obesity, and congestive heart failure - The roles of diabetes in the development of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD and strokes - The role of obesity in the development of cardiometabolic conditions - The role of incretins in the management of diabetes, obesity, and related complications - Comprehensive management of diabetes, through addressing obesity, hypertension, dyslipidemia and hyperglycemia - The role of SGLT2i & GLP1ra for primary prevention of cardiovascular morbidity & mortality in patients with T2D - The evidence supporting the use of SGLT2 inhibitors and GLP1ra`s to reduce cardiovascular morbidity & mortality in patients with T2D and established CVD - Fatty liver disease and its relationship to diabetes and CVD - The role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD - The impact on clinical practice of recent CVD, CHF & CKD outcome trials - The pathogenesis of liver and muscle insulin resistance, the role of adipose tissue and of the mitochondria in hyperglycemia and ASCVD - Best practices for the prevention and management of CHF - The impact on clinical practice of lipid CV outcome trials, including IMPROVE -IT, FOURIER, REDUCE -IT, ODYSSEY-Outcomes - The role of Coagulation and new anti-coagulation agents in prevention of CVD and CVA - The Cardiorenal Syndrome - Reducing morbidity and mortality through being able to match the correct medications to the appropriate patients Who should Attend - Endocrinologists - Cardiologists - Oncologists - Gastroenterologists - Diabetologists - Internists - Pediatricians - OBGYNs - Nurse practitioners - Dietitians - Pharmacists - Other health care professionals
Venue
Los Angeles, United States
Open Hilton Hotel Universal City, Los Angeles, CA in maps ↗No street address is on file for this listing — what the organizer gave is above. Suggest the venue address →
Similar conferences
Health & Medicine · Cardiology
International Conference on Cardiology 2026
Health & Medicine · Cardiology
Cardiology Conference-CVC 2026
Health & Medicine · Cardiology



